Oral treatments for fungal infections of the skin of the foot.

Bell-Syer, Sally EM; Hart, Rachel; Crawford, Fay; Torgerson, David; Tyrrell, Wendy; Russell, Ian

doi:10.1002/14651858.cd003584

Cited by 38 publications

(11 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…administration of terbinafine 62 and itraconazole 63 is effective in the treatment of tinea pedis. A systematic review reached a similar conclusion 64 . In a systematic review of four studies comparing terbinafine with itraconazole, 65–68 no significant differences were found between the drugs 64 …”

Section: Cq2: Is An Oral Antifungal Agent Recommended For Tinea Pedismentioning

confidence: 88%

Guidelines for the management of dermatomycosis (2019)

Mochizuki

Tsuboi

Iozumi

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

The "Guidelines for the management of dermatomycosis" of the Japanese Dermatological Association were first published in Japanese in 2009 and the Guidelines Committee of the Japanese Dermatological Association revised it in 2019. The first guidelines was prepared according to the opinions of the Guidelines Committee members and it was of educational value. The revised version is composed of introductory descriptions of the disease concepts, diagnosis, medical mycology and recent advances in treatment, along with clinical questions (CQ), which is intended to help in general practice for dermatologists. The CQ are limited to those involved in therapy but include some of the recently launched antifungal agents. The level of evidence and the degree of recommendation for each item were reviewed by the committee based on clinical studies published by 2018. For rare dermatomycoses, recommendations by the committee are described in the guidelines. In this field, there are still few good quality studies on treatment. Periodic revision in line with new evidence is necessary.

show abstract

Section: Cq2: Is An Oral Antifungal Agent Recommended For Tinea Pedismentioning

confidence: 88%

Guidelines for the management of dermatomycosis (2019)

Mochizuki

Tsuboi

Iozumi

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Topical therapy with the fungicidal allylamine antifungals is associated with slightly higher cure rates and shorter courses of treatment than therapy with the fungistatic azoles. 34 , 35 , 36 However, this therapeutic advantage is offset by their significantly higher cost. 37 Therefore, as the present study was conducted in a public health system setting, we may infer that therapeutic options had to be adapted to meet the patients' economic status.…”

Section: Discussionmentioning

confidence: 99%

“…This agent is considered the standard of care, particularly for tinea capitis ( Table 4 ). 35 As compared with ketoconazole, griseofulvin produces excellent outcomes, with a faster onset of action and no side effects. 32 , 45…”

Section: Discussionmentioning

confidence: 99%

Clinical, epidemiological, and therapeutic profile of dermatophytosis

Pires

Cruz

Lobato

et al. 2014

An. Bras. Dermatol.

101

View full text Add to dashboard Cite

BACKGROUNDThe cutaneous mycoses, mainly caused by dermatophyte fungi, are among the most common fungal infections worldwide. It is estimated that 10% to 15% of the population will be infected by a dermatophyte at some point in their lives, thus making this a group of diseases with great public health importance.OBJECTIVETo analyze the clinical, epidemiological, and therapeutic profile of dermatophytosis in patients enrolled at the Dermatology service of Universidade do Estado do Pará, Brazil, from July 2010 to September 2012.METHODA total of 145 medical records of patients diagnosed with dermatophytosis were surveyed. Data were collected and subsequently recorded according to a protocol developed by the researchers. This protocol consisted of information regarding epidemiological and clinical aspects of the disease and the therapy employed.RESULTSThe main clinical form of dermatophyte infection was onychomycosis, followed by tinea corporis, tinea pedis, and tinea capitis. Furthermore, the female population and the age group of 51 to 60 years were the most affected. Regarding therapy, there was a preference for treatments that combine topical and systemic drugs, and the most widely used drugs were fluconazole (systemic) and ciclopirox olamine (topical).CONCLUSIONThis study showed the importance of recurrent analysis of the epidemiological profile of dermatophytosis to enable correct therapeutic and preventive management of these conditions, which have significant clinical consequences, with chronic, difficult-totreat lesions that can decrease patient quality of life and cause disfigurement.

show abstract

“…[3–22] A discrepancy was observed between DPCO list and list of essential medicines for fungal infections recommended by WHO and NLEM, India [Table 4]. …”

Section: Resultsmentioning

confidence: 99%

A study to evaluate the price control of antifungal medicines and its practical applicability

et al. 2012

View full text Add to dashboard Cite

Background:Superficial fungal infections are common and treatment imposes economic burden on the patients. Government of India had introduced price control over griseofulvin and tolnaftate in 1995; however, this measure can only benefit the needy if the policy is harmonized with the health-care service provider, that is, dermatologists. The aim of this study was to evaluate the existing Government mechanisms over price control of antifungal medications and its reach to the people-in-need.Materials and Methods:A questionnaire-based, cross-sectional study was carried out over a period of 6 months. Questionnaire was mailed to members of a state branch of Indian Association of Dermatologists, Venereologists, and Leprologists. Responses reaching investigators within 2 months from the date of mailing were finally analyzed.Results:Among 93 (41.33%) respondents, only 6 (6.5%) were aware of existing price control over griseofulvin but none about tolnaftate. Thirty-nine (41.9%) respondents were in favor of introducing price control on terbinafine and 42 (45.2%) for itraconazole. The topically preferred antifungals were primarily azoles and terbinafine, while among systemic antifungals, dermatologists mostly preferred fluconazole and terbinafine. The choice of antifungals by the dermatologists matched with the evidence-based dermatology data.Conclusion:Currently, price-controlled antifungal drugs are less commonly used by practitioners. Although the dermatologists favor price control, the initiative undertaken by the Government has not reached them. This shows the need to bridge the gap between policy makers and health-care service providers to help the ailing population.

show abstract

Oral treatments for fungal infections of the skin of the foot.

Cited by 38 publications

References 37 publications

Guidelines for the management of dermatomycosis (2019)

Guidelines for the management of dermatomycosis (2019)

Clinical, epidemiological, and therapeutic profile of dermatophytosis

A study to evaluate the price control of antifungal medicines and its practical applicability

Contact Info

Product

Resources

About